芬维A胺对人肝癌细胞株HepG2增殖与细胞凋亡的影响

摘要

目的：探讨分子靶向药物芬维A胺(Fenretinide)在体外对人肝癌细胞株HepG2的细胞增殖与细胞周期的影响。方法体外培养人肝癌HepG2细胞，实验组在培养液中加入不同浓度的芬维A胺(2.5μmol/L、5μmol/L、10μmol/L、20μmol/L)，对照组培养液中不加芬维A胺，分别孵育48 h后，采用MTT法检测芬维A胺对HepG2细胞增殖的影响，流式细胞仪分析细胞周期和凋亡率。结果芬维A胺能明显抑制HepG2细胞增殖，呈时间和剂量依赖性；芬维A胺处理HepG2细胞72 h，可使G0~G1期细胞比例升高，G2~M、S期比例明显下降，凋亡率明显上升(P<0.05)。结论芬维A胺对体外人肝癌HepG2细胞具有明显的抑制作用，主要表现为抑制增殖和促进凋亡。%Objective To investigate the depressant effects of fenretinide on human liver cancer cell line HepG2 cells in vitro. Methods Human liver carcinoma line HepG2 cells were cultured in vitro. The HepG2 cells of the test group were incubated in the medium with fenretinide at different concentrations (2.5μmol/L, 5μmol/L, 10μmol/L, 20μmol/L). The cells of the control group were incubated in the medium for 48 hours. MTT method was used to de-tect the antiproliferative ratio of fenretinide on HepG2 cells, and flow cytometry was applied to analyze the cell cycle and apoptotic ratio. Results Fenretinide could obviously inhibit the proliferation of HepG2 cells, showing time-and dose-dependent effects. 72 hours after the HepG2 cells were treated with fenretinide, the percentage of HepG2 cells in G0~G1 period increased, and that in G2~M period and S period decreased, with the aopototic ratio of HepG2 cells in-creased significantly (P<0.05). Conclusion Fenretinide can inhibit proliferation and promote apoptosis of human liver cancer cell line HepG2 cells in vitro.